Tonix Pharmaceuticals stock halted ahead of FDA approval news
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) stock has reached a 52-week low, touching down at $2.04, marking a 73% decline from its 52-week high of $7.67. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations. This new low comes as a significant downturn for the biopharmaceutical company, which has seen its stock price decline by 51.62% over the past year. Investors are closely monitoring CASI’s performance, as the company navigates through the pressures of the pharmaceutical industry, which include rigorous regulatory hurdles and intense competition. With a current market capitalization of $34.7 million and analysts setting a target price of $6.00, the stock’s potential remains uncertain. InvestingPro subscribers can access 11 additional investment tips and comprehensive financial metrics to better evaluate CASI’s prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.